HUMA Stock Analysis: Buy, Sell, or Hold?
HUMA - Humacyte, Inc. Common Stock
$0.85
0.04 (5.16%)
▲
5d:
+28.6%
30d:
+25.44%
90d:
-17.72%
HOLD
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 12, 2026
12d
Smart Money Accumulation
HUMA is down 4.2% this week, but smart money is accumulating calls. Top strike: $1 2026-06-18 with 970 OI. Call ratio: 100% View Scanner →
Strength: 7.1/10
Get Alerted When HUMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: HUMA is 8.7% above its trading range ($0.78). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: HUMA is 8.7% above its trading range ($0.78). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: HUMA is currently trading at $0.85, which is considered extended relative to its 30-day fair value range of $0.62 to $0.78.
Technical Outlook: Technically, HUMA is in a strong downtrend. The price is approaching resistance at $0.83. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: HUMA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.10 (+502.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HUMA is in a strong downtrend. The price is approaching resistance at $0.83. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: HUMA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.10 (+502.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.62 -
$0.78
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+8.7% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.2%)
- BULLISH: Trading 502.1% below Wall St target ($5.10)
- CAUTION: Extended 8.7% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$0.62 -
$0.78
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.65
Resistance Level
$0.83
Current Trend
Strong Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.62
Wall Street Target
$5.10
(+502.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: April 29, 2026 4:20 AM ET
Data refreshes hourly during market hours. Next update: 5:20 AM
Data refreshes hourly during market hours. Next update: 5:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HUMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 59 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$878 | 58 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
